3DBT's City-MixTM is a patented non-toxic culture media supplement that acts as an effective 'cell booster'. It is composed of a specific formulation that facilitates a process called macromolecular crowding which has a number of advantages over traditional media used in the production of cultivated meat. These include higher production yields; the need for fewer expensive supplements to significantly reduce operating costs; the elimination of animal-derived serum, such that no animals suffer in the production process; and removal of the requirement for any plant-based scaffold, blend or filler alternatives.
Go-to-Market Bio-Pharmaceutical Update
3DBT has made significant progress following the implementation of the second phase of the Company’s go-to-market strategy which, in addition to the Cultured Meat and Cellular Agricultural markets, is now addressing the Bio-Pharmaceutical industry by partnering with those working in gene therapy, stem cells and regenerative medicine; life science companies; and academia.
The Company has partnered with Benzol – a world leader in the science distribution sector - to help commercialise and act as a distributor of City-MixTM across
3DBT has also engaged directly with one of the leading global suppliers to pharmaceutical companies. The Fortune 500 company is a world leader in providing solutions for cellular analysis and synthetic biology. The company has currently purchased several vials of City-MixTM for evaluation to be used in its media formulation and help reduce costs.
Meanwhile, one of the world’s leading stem cell companies, which specialises in converting stem cells into fat tissue, is also evaluating the use of City-MixTM in its production process to help increase efficacy and reduce costs. If successful, the partnership will provide a significant opportunity for scalable volume production of City-MixTM.
The Company will continue to deliver its go to market strategy and increase the licensing of City Mix™ through engagements with distributors across target global markets.
Dr.
Cultivated Meat Update
Since March, 3DBT has continued developing commercial partnerships with cellular agriculture companies. Two companies began purchasing the product in
3DBT will continue to develop its partnerships programme with established food manufacturers throughout 2023, including across
Update on US Listing
As announced on
An Investor brief fact sheet can be viewed on the BSF website at the following bit.ly/bsf202306
For further enquiries, please visit www.bsfenterprise.com or contact:
| Via SEC Newgate below |
| |
0207 186 9000 0207 186 9927 | |
SEC Newgate (U.K. | |
020 3757 6882 BSF@secnewgate.co.uk |
Scott Powell +1 646 893 5835 x2
Lisa Gray info@skylineccg.com
About
It owns 100% of 3D Bio-Tissues (3DBT), a tissue engineering with patent-protected IP that is already producing human corneas to help restore vision to millions of people. Building on this success, it aims to produce the
BSF aims to deliver growth to shareholders through the continued commercialisation of 3DBT's IP, which has multiple applications, as well as through M&A. It aims to acquire a suite of technologies that underpins the development of tissue templating for corneas, meat and leather, and license out the IP to manufacturers, wholesalers and distributors to help manufacture the products at scale.
Safe Harbor Statement
This press release contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.
Source:
2023 GlobeNewswire, Inc., source